Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

InsideArbitrage Potential Deal Alert: Life Sciences Firm Abcam (ABCM) Receives Takeover Interests

  • June 18, 2023


Stock Abcam Symbol ABCM
Date Announced 06/16/2023 Source Bloomberg
Type Company Seeking Strategic Alternatives
Date of Confirmation: 08/28/2023 Price at Confirmation: $22.48
Potential Profit: 0.76% Annualized Profit: 3.81%

According to Bloomberg, Abcam (ABCM), the biotechnology supplier has received multiple takeover approaches over recent weeks.


June 23, 2023: Abcam (ABCM), announced that, having extensively engaged with shareholders, the Board of Directors has unanimously decided to initiate a process to explore strategic alternatives including a potential sale of the company.

June 26, 2023: Abcam (ABCM) founder Jonathan Milner announces suspension of proxy solicitation to allow Abcam’s Board of Directors to run a comprehensive review of strategic alternatives.

June 30, 2023: According to Bloomberg, Abcam Plc (ABCM), the biotechnology supplier that’s exploring a sale, is attracting initial interest from US life sciences companies Danaher and Agilent Technologies (A).

August 25, 2023: According to Reuters,  Danaher Corp (DHR) is in the lead to acquire Abcam Plc (ABCM) and Abcam believes that Danaher’s all-cash offer is superior to a rival bid from Agilent Technologies (A).

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.